Wordt geladen...
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK(1) and NK(3) receptors
BACKGROUND AND PURPOSE: Clinical results of osanetant and talnetant (selective-NK(3) antagonists) indicate that blocking the NK(3) receptor could be beneficial for the treatment of schizophrenia. The objective of this study was to characterize the in vitro and in vivo properties of a novel dual NK(1...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Blackwell Publishing Ltd
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3042203/ https://ncbi.nlm.nih.gov/pubmed/21039418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2010.01096.x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|